bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
288 hedge funds and large institutions have $9.81B invested in bluebird bio in 2019 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 106 increasing their positions, 79 reducing their positions, and 28 closing their positions.
132% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 28
62% more capital invested
Capital invested by funds: $6.04B → $9.81B (+$3.77B)
62% more call options, than puts
Call options by funds: $141M | Put options by funds: $87.5M
34% more repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 79
15% more funds holding
Funds holding: 251 → 288 (+37)
0.13% more ownership
Funds ownership: 8.63% → 8.76% (+0.13%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
+$64.7M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$50.4M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$42.4M |
| 4 |
HM
HealthCor Management
New York
|
+$41.2M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$35.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$38.4M |
| 2 |
Two Sigma Investments
New York
|
-$25.3M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$21M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$10.9M |
| 5 |
AG
Artal Group
Luxembourg
|
-$10.2M |
BLUE Hedge Fund Activity: Q1 2019 in Review
288 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q1 2019, worth a combined $9.81B — up 62% from $6.04B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new BLUE positions and 28 closed out — a net gain of 37 holders — while 106 added to existing stakes and 79 trimmed.
The largest buyer was Marshall Wace North America, opening a new position worth an estimated $64.7M. The largest seller was OrbiMed, exiting entirely with an estimated $38.4M sold.
- 288 institutional investors held bluebird bio (BLUE) as of Q1 2019, up from 251 in Q4 2018.
- Funds reported $9.81B of bluebird bio stock for Q1 2019, up 62% quarter-over-quarter.
- 65 funds opened new bluebird bio positions in Q1 2019 and 28 closed out, a net change of +37 holders.
- The largest bluebird bio buyer in Q1 2019 was Marshall Wace North America, an estimated $64.7M added.
- The largest bluebird bio seller in Q1 2019 was OrbiMed, an estimated $38.4M sold.
Based on aggregated 13F filings for Q1 2019.